Primary Progressive Multiple Sclerosis Market Analysis 2014 - 2020 Available In
Posted by Nilesh Londhe on May 28th, 2019
Multiple sclerosis (MS), which is also referred as disseminated sclerosis, is an inflammatory disease of the nervous system. It is mainly characterized by the disruption of the nerve cells of the spinal cord and the brain of an affected individual, which results in the loss of ability to communicate along with various other physical, mental as well as psychiatric problems.
Primary progressive multiple sclerosis (PPMS) is a type of MS in which the neurological functioning steadily deteriorates with no distinct relapses (also known as attacks or exacerbations) or fixed period of remissions. The rate of progression of PPMS may differ from person to person as well as over time, that may show signs of temporary improvement, however, the disease progression remains consistent.
At present, several forms of relapsing MS are increasingly affecting large number of individuals worldwide, such as, secondary-progressive MS, relapsing remitting MS, progressive relapsing MS and primary progressive MS. These individuals continuously experience relapses, which are distinct inflammatory attacks mainly on the myelin sheath of the nerve fibers. In addition, PPMS is characterized by least inflammation among different types of relapsing MS. PPMS also results in very fewer brain lesions or plaques than in patients with other forms of relapsing MS; these lesions also contain very small amount inflammatory cells. Individuals suffering from PPMS have more lesions on spinal cord than the brain.
Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3016
Thus, these differences have made PPMS difficult to diagnose as well as treat than other forms of relapsing MS. At present, different diagnostic tests are being utilized for effectively diagnosing and employing proper treatment procedure in place. Some of the diagnostic tests include Magnetic Resonance Imaging (MRI) Scans, Lumbar Puncture and other simple electrical stimulation tests. Major therapeutics available for the symptomatic treatment of PPMS include Baclofen, Dantrolene, Oxybutynin, Detrusitol, Amantadine, Modafinil, Clonazepam, Gabapentin and Pregabalin. However, several manufacturers are developing specific PPMS treatment drugs which are in different stages of clinical trials, which include Fingolimod and Masitinib.
Some of the major driving factors for the growth of this market include increasing prevalence of neurological disorders, rising demand for advanced therapeutics for the treatment of PPMS and increasing awareness and affordability of the population in developing nations. Multiple sclerosis is the most widespread neurological disorder that affects individuals of any age, but is mainly diagnosed between 20 to 40 years of age. According to multiplesclerosis.net (Health Union, U.S.), there are more than 2.5 million people suffering from multiple sclerosis, which are at different stages of the disease. Among all forms of MS, 10% to 15% individuals suffer from PPMS, which are difficult to diagnose as well as treat; hence, high demand for advanced therapeutics for its treatment will further boost the growth of this market.
Geographically, North America and Europe are expected to dominate the PPMS market. Major factors that can be responsible for their dominance in this market are high prevalence of MS and high demand for therapeutic drugs for effective treatment of PPMS in these regions. According to multiplesclerosis.net more than 500,000 people suffer from MS in Europe and around 400,000 people suffer from it only in the U.S. Thus, high prevalence rate of MS and PPMS will contribute towards the growth of this market in the region. Some of the major players having their drugs for SPMS in different phases of clinical trials, include, F. Hoffmann-La Roche Ltd. and Innate Immunotherapeutics Limited.
Like it? Share it!
About the AuthorNilesh Londhe
Joined: May 6th, 2019
Articles Posted: 89
More by this author